Key facts
- This page summarizes Robert Iannone's Form 4 filing for Jazz Pharmaceuticals plc (JAZZ).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 09 Jun 2021, 18:57.
Robert Iannone - 05 Jun 2021 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)
- Reporting relationship
- EVP R&D, Chief Medical Officer
- Issuer ticker
- JAZZ
- Reported as of
- 05 Jun 2021
- Net transaction value
- -$212,823
- SEC form
- 4
- Accepted by SEC
- 09 Jun 2021, 18:57:13 UTC
- Next SEC filing
- 21 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- By: /s/Adam Guttmann, as attorney in fact For: Robert Iannone
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert Iannone filed Form 4 for Jazz Pharmaceuticals plc (JAZZ) on 09 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$212,823.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
JAZZ
transaction
Ordinary Shares
Tax liability
- Transaction value
- $212,823
- Shares
- -1,206
- Change %
- -4%
- Price
- $176.47
- Shares after
- 29,086
- Date
- 05 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
Footnote F2
Includes 147 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 28, 2021.